ZNTL

Zentalis Pharmaceuticals, Inc.

8.81 USD
-0.03 (-0.34%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Zentalis Pharmaceuticals, Inc. stock is down -27.01% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.